Claims
- 1. A method of modulating cell proliferation or apoptosis comprising modulating psoriastatin activity.
- 2. The method of claim 1, wherein apoptosis is inhibited.
- 3. The method of claim 1, wherein apoptosis in promoted.
- 4. The method of claim 3, wherein apoptosis is promoted by inhibiting psoriastatin activity.
- 5. The method of claim 4, wherein psoriastatin activity is inhibited by administering a psoriastatin antagonist.
- 6. The method of claim 4, wherein psoriastatin activity is inhiibted by administering an antisense psoriastatin nucleic acid.
- 7. The method of claim 4, wherein psoriastatin activity is inhiibted by administering an anti-psoriastatin antibody.
- 8. A method of treating a mammal at risk for a disorder characterized by unwanted cell proliferation or less than wild type levels of apoptosis comprising:
administering to the mammal a treatment which inhibits an activity of a psoriastatin type I or psoriastatin type II protein.
- 9. The method of claim 8, wherein an activity of psoriastatin type I or psoriastatin type II protein is inhibited by administering a therapeutically effective amount of a nucleic acid encoding an antagonist of a psoriastatin polypeptide.
- 10. The method of claim 8, wherein an activity of a psoriastatin type I or psoriastatin type II protein is inhibited by administering a therapeutically effective amount of an antisense psoriastatin nucleic acid.
- 11. The method of claim 8, wherein an activity of a psoriastatin type I or psoriastatin type II protein is inhibited by administering a therapeutically effective amount of an anti-psoriastatin antibody.
- 12. The method of claim 8, wherein said disorder is cancer.
- 13. The method of claim 8, wherein said disorder is psoriasis.
- 14. A method of evaluating a compound for the ability to interact with a psoriastatin type I or a psoriastatin type II polypeptide including contacting the compound with the psoriastatin polypeptide, and evaluating ability of the compound to interact with or form a complex with the psoriastatin polypeptide.
- 15. The method of claim 14, further comprising evaluating the effect of said compound on apoptosis.
- 16. A method of making a psoriastatin polypeptide having a non-wild amino acid sequence comprising altering the sequence of a psoriastatin polypeptide and testing the altered polypeptide for the ability to modulate apoptosis or cell growth.
- 17. The method of claim 16, wherein said alteration results in a conservative amino acid change.
- 18. The method of claim 16, wherein said alteration results in a non-conservative amino acid change.
- 19. A method of evaluating a compound for the ability to modulate psoriastatin polypeptide-mediated regulation of cathepsin L comprising contacting the compound with either or both of a psoriastatin polypeptide and cathepsin L, and determining the effect of the compound on the ability of psoriastatin to inhibit cathepsin L.
- 20. A human cell transformed with a nucleic acid which encodes a psoriastatin polypeptide.
- 21. A method of treating a skin disorder including administering to a subject a therapeutically effective amount of a compound which inhibits psoriastatin.
- 22. A method of identifying active fragments or analogs of a psoriastatin polypeptide comprising identifying a compound which interacts with a psoriastatin polypeptide and determining the ability of the compound to bind the fragment or analog.
Parent Case Info
[0001] This application claims benefit from the Previously filed Provisional Application No. 60/013,755 filed Mar. 20, 1996 and from 60/005,679 filed on Oct. 17, 1995, which are hereby incorporated by reference.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60013755 |
Mar 1996 |
US |
|
60005679 |
Oct 1995 |
US |